U.S. Markets open in 2 hrs 12 mins

Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?

Zacks Equity Research
Halozyme Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Investors certainly have to be happy with Reata Pharmaceuticals, Inc. RETA and its short term performance. After all, the stock has jumped by 11.9% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for RETA?

While we can never know for sure, it is pretty encouraging that estimates for RETA have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks. You can see the complete list of today’s Zacks #1 Rank stocks here.

 

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Reata Pharmaceuticals, Inc. (RETA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research